Cargando…

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults

A novel Staphylococcus aureus 4-antigen vaccine (SA4Ag) is under development, comprising capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) conjugated to CRM(197), recombinant protein clumping factor A (rmClfA), and recombinant manganese transporter protein C (MntC). We evaluated SA4Ag safety,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Megumi, Yonemura, Takuma, Baber, James, Shoji, Yasuko, Aizawa, Masakazu, Cooper, David, Eiden, Joseph, Gruber, William C., Jansen, Kathrin U., Anderson, Annaliesa S., Gurtman, Alejandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314418/ https://www.ncbi.nlm.nih.gov/pubmed/30084709 http://dx.doi.org/10.1080/21645515.2018.1496764

Ejemplares similares

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)
por: Creech, C Buddy, et al.
Publicado: (2019)

599 Rapid rises in antibody titers observed following single dose administration of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) to healthy adults
por: Frenck, Robert W., et al.
Publicado: (2014)

Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection
por: Anderson, Annaliesa S., et al.
Publicado: (2016)

Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial
por: Hassanzadeh, Hamid, et al.
Publicado: (2023)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study
por: Scully, Ingrid Lea, et al.
Publicado: (2017)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine
por: Peterson, James T, et al.
Publicado: (2021)

Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine
por: Falsey, Ann R, et al.
Publicado: (2021)

1098 The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions
por: Schmoele-Thoma, Beate, et al.
Publicado: (2014)

A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years
por: Kitchin, Nicholas, et al.
Publicado: (2020)

385. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2
por: Paulsen, Grant C, et al.
Publicado: (2023)

636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
por: Remich, Shon A, et al.
Publicado: (2020)

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
por: Haranaka, Miwa, et al.
Publicado: (2021)

The impact of human vaccines on bacterial antimicrobial resistance. A review
por: Jansen, Kathrin U., et al.
Publicado: (2021)

1941. Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine With Influenza Vaccine in Older Adults
por: Baber, James A, et al.
Publicado: (2023)

362. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series
por: Sher, Lawrence, et al.
Publicado: (2023)

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
por: Baber, James, et al.
Publicado: (2022)

The role of vaccines in fighting antimicrobial resistance (AMR)
por: Jansen, Kathrin U., et al.
Publicado: (2018)

Auxin-Induced SaARF4 Downregulates SaACO4 to Inhibit Lateral Root Formation in Sedum alfredii Hance
por: Xu, Dong, et al.
Publicado: (2021)

Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine
por: Scully, Ingrid L., et al.
Publicado: (2014)

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
por: Walsh, Edward E., et al.
Publicado: (2020)

Potential impact of the bivalent rLP2086 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease
por: Anderson, Annaliesa S., et al.
Publicado: (2013)

Expression and lytic efficacy assessment of the Staphylococcus aureus phage SA4 lysin gene
por: Mishra, Anil Kumar, et al.
Publicado: (2013)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Regulation of Staphylococcus aureus MntC Expression and Its Role in Response to Oxidative Stress
por: Handke, Luke D., et al.
Publicado: (2013)

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
por: Simões, Eric A F, et al.
Publicado: (2023)

A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec
por: Gilca, Rodica, et al.
Publicado: (2018)

Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease
por: Scully, Ingrid L., et al.
Publicado: (2021)

Vaccination strategies for the prevention of meningococcal disease
por: Vuocolo, Scott, et al.
Publicado: (2018)

Uncommon structural and bonding properties in Ag(16)B(4)O(10)
por: Kovalevskiy, Anton, et al.
Publicado: (2019)

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: An open-label trial
por: Shiramoto, Masanari, et al.
Publicado: (2014)

Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial
por: Absalon, Judith, et al.
Publicado: (2021)

Meningococcal serogroup B vaccines: Estimating breadth of coverage
por: Donald, Robert G. K., et al.
Publicado: (2016)

A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children
por: Frenck, Robert W., et al.
Publicado: (2023)

Current perspectives of SA-4-1BBL in immune modulation during cancer
por: Zhou, Shu-Ni, et al.
Publicado: (2018)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

High-Pressure Behavior and Disorder for Ag(2)ZnSnS(4) and Ag(2)CdSnS(4)
por: Küllmey, Tim, et al.
Publicado: (2021)

Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer
por: Blakney, Anna K., et al.
Publicado: (2020)

Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial
por: Inoue, Megumi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bcga9suktjfkehtb8sk63glpd1